Mauna Kea Technologies Announces 33 Abstracts on Cellvizio(R) to Be Presented at Digestive Disease Week 2011

PARIS--(Marketwire - May 5, 2011) - Mauna Kea Technologies, a leader in endomicroscopy, announced that 33 Cellvizio or pCLE-related abstracts would be presented at Digestive Disease Week (DDW) 2011, which runs from May 7 to 10 in Chicago. Eleven of the 33 abstracts will be delivered through oral presentations, of which four are to be presented in plenary sessions.

Data highlights include the final results of the company's "Cellvizio ERCP registry trial" designed to determine the impact of pCLE on the diagnosis and treatment of patients with indeterminate bilio-pancreatic strictures. Supplementary data from the company's multicentric, randomized, controlled trial on Barrett's esophagus which demonstrates that Cellvizio significantly improves pre-cancerous lesion detection in patients with Barrett's esophagus, will also be presented at the conference.

"This year's DDW is a significant event in the history of Mauna Kea Technologies and for the field of endomicroscopy," said Sacha Loiseau, CEO and Founder, Mauna Kea Technologies. "The final results of the largest endomicroscopy clinical studies ever conducted in Barrett's esophagus and bile duct cancer will be presented, as well as exciting new clinical research centered on indications such as pancreatic cancer, inflammatory bowel disease and graft-versus-host disease. These data will add to the extensive body of clinical evidence confirming that pCLE helps physicians to confidently recommend appropriate therapeutic procedures based on more comprehensive disease characterization. We're also extremely excited to unveil the Cellvizio 100 Series which offers our users significant upgrades to help them integrate pCLE into their endoscopy suites."

The Cellvizio 100 Series incorporates key upgrades including enhanced image quality and a "Cine Review" feature that allows physicians to focus on a single frame of clinical relevance for as long as necessary. Other features include an improved user interface, faster start up and shut down times, multiple synchronized controls and video outputs, data exchange allowing images to be exported to electronic medical records or databases for research studies and an integrated mini-probe design to ease handling from disinfection to storage. The Cellvizio 100 Series is pending 510K clearance from the U.S. Food and Drug Administration (FDA) and is not currently for sale in the United States.

Members of the media are invited to attend the presentations and to schedule a one-on-one meeting with the company at the McCormick Place (MCP) Convention Center, booth #1321. To arrange an interview or to receive further information, contact Erich Sandoval at esandoval@lazarpartners.com.

For a full listing of abstracts and presentations, go to: http://newsletter.maunakeatech.com/data/ddw2011planner.pdf

Data presented at DDW are embargoed until the time it is presented.

About DDW
DDW is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases, the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy and the Society for Surgery of the Alimentary Tract, DDW takes place May 7 - 10, 2011, at McCormick Place, Chicago, IL. The meeting showcases approximately 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. For more information, visit www.ddw.org.

About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company and a leader in endomicroscopic innovation. The company researches, develops and markets innovative tools to visualize and detect abnormalities in the gastro-intestinal and pulmonary tracts. Its flagship product, Cellvizio®, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers with high resolution cellular views of tissue inside the body. Large, international, multi-center clinical trials have demonstrated Cellvizio's ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use in the GI and pulmonary tracts.